Target Audience (click to view)
This activity is designed to meet the needs of physicians.
Learning Objectives(click to view)
Upon completion of the educational activity, participants should be able to:
- Define the needs that existed for the 2013 update to the American College of Cardiology/American Heart Association guideline on the assessment of cardiovascular risk.
- Describe key recommendations made by the 2013 update to the American College of Cardiology/American Heart Association guideline on the assessment of cardiovascular risk.
Method of Participation(click to view)
Statements of credit will be awarded based on the participant reviewing monograph, correctly answer 2 out of 3 questions on the post test, completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.akhcme.com/pwapril6. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. at firstname.lastname@example.org.
Credit Available(click to view)
CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Physician’s Weekly’s. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support(click to view)
There is no commercial support for this activity.
Disclosures(click to view)
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Disclosure of Unlabeled Use & Investigational Product(click to view)
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer(click to view)
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Faculty & Credentials(click to view)
Christopher Cole- Senior Editor
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
Dorothy Caputo, MA, BSN, RN- CE Director of Accreditation
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
AKH planners and reviewers have no relevant financial relationships to disclose.
Take CME(click to view)
Cardiovascular disease (CVD) caused by atherosclerosis continues to be the leading cause of death and is a major cause of disability as well as a significant source of healthcare costs in the United States. In 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) released an updated clinical practice guideline to help clinicians better identify adults who may be at high risk for developing atherosclerotic CVD. The update, published jointly in the Journal of the American College of Cardiology and Circulation, also provides recommendations for identifying patients who could benefit from lifestyle changes or drug therapy to help prevent CVD.
“These guidelines were last updated about 10 years ago,” says David C. Goff, Jr., MD, PhD, who co-chaired the ACC/AHA risk assessment guideline writing group. “Since that time, we have collected a large amount of research that has further enhanced our understanding of how best to care for these patients and improve our approaches to determining who should get specific types of preventive treatments.”
A key goal of the ACC/AHA guideline is to ensure that preventive treatments—especially lifestyle changes and drug treatment—are used in those who are most likely to benefit from them. To do this, the guideline includes high-quality risk assessment methods that use risk factors that are known to lead to atherosclerosis (Table 1). Factors such as age, cholesterol levels, blood pressure, smoking, and diabetes can be easily collected by clinicians and then integrated into a risk score to guide care and prompt discussions with patients.
“The vast majority of heart attacks and strokes could be prevented if patients knew their risk and took actions to reduce that risk,” explains Dr. Goff. “That action starts with adopting a healthy lifestyle. For some patients at higher risk, it also includes medications. Unfortunately, both patients and physicians often underestimate CVD risk, especially when considered over a lifespan.” The recommendations offer clinicians the most up-to-date, comprehensive guidance and an algorithm about assessing risk so they can work with patients to prevent heart attacks and stroke.
According to Dr. Goff, about one in three U.S. adults who have not yet been diagnosed with CVD and have not had a heart attack or stroke are at high enough risk that they could benefit from primary prevention with medications, most notably statins, to lower their risk. “The recommendations help clinicians recognize which patients are candidates for statins for both primary and secondary prevention,” he says. “For primary prevention, the information on risk helps physicians identify patients who should be considered for statin therapy to prevent heart attacks and strokes.”
The ACC/AHA guideline has also been broadened to include assessment for risk of stroke. “By including stroke in the algorithm, we can better calculate overall cardiovascular risk,” Dr. Goff says. “This is especially important for women and African Americans at high risk for stroke.” In the past, cardiovascular risk assessment included only coronary heart disease. Furthermore, the recommendations help clinicians and patients look beyond traditional short-term (10-year) risk estimates to predict lifetime risk of developing heart disease and stroke.
“The vast majority of heart attacks and strokes could be prevented
if patients knew their risk and took actions to reduce that risk.”
There is some evidence that the known risk factors have somewhat different effects on certain genders and races. The guidelines provide new gender- and ethnicity-specific formulas for predicting risk in African-American and non-Hispanic Caucasian women and men. The algorithm allows clinicians to be selective about whose risk for CVD is high enough that it would merit considering drug therapy to help prevent it.
Newer Risk Measures
The ACC/AHA work group also provided recommendations about the clinical usefulness of newer markers of risk. These measures include family history of premature CVD, coronary artery calcium scores, high-sensitivity C-reactive protein levels, and ankle brachial index (Table 2). While these measures are not recommended for routine use in risk assessment, they have stood out as potentially helpful in some cases. “These measures have shown the greatest promise,” says Dr. Goff. “They may help inform treatment decision making when patients or providers are on the fence after quantitative risk assessment.”
The risk for developing atherosclerosis accrues over time and is a function of lifelong exposure to risk factors. Accordingly, Dr. Goff says it is never too early for clinicians to focus on determining risk. “It’s hoped that these algorithms will be incorporated into electronic health records to help clinicians easily and automatically calculate risk,” he says. “In turn, clinicians can be prompted to discuss individualized options for lowering risks. In the future, it’s anticipated that more research will provide an even better understanding of the optimal means for using short- and long-term cardiovascular risk assessment in all race and ethnic groups, across different ages, and between men and women.”
Readings & Resources (click to view)
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7 [Epub ahead of print]. Available at: http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98.
Lloyd-Jones DM, Leip EP, Larson MG et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-495.
Pencina MJ, D’Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation. 2009;119:3078-3084.
Moyer VA. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: u.s. Preventive services task force recommendation statement. Ann Intern Med. 2013;159:342-348.